Spermosens operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical support and potential fertilization. The largest operations are found in the Nordic market.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Mount Nebo Capital | 24,95 | 24,95 | 2025-03-04 |
| Avanza Pension | 13,88 | 13,88 | 2025-12-23 |
| Nordnet Pensionsförsäkring | 5,27 | 5,27 | 2025-12-23 |
| UNITY Innovation Alliance AG | 5,17 | 5,17 | 2025-03-04 |
| Henrik Ruö Jensen | 4,46 | 4,46 | 2025-12-23 |
| Michael Kantor | 4,12 | 4,12 | 2025-12-23 |
| Peter Nilsson | 3,33 | 3,33 | 2025-12-23 |
| Flexmedical Solutions Limited | 3,08 | 3,08 | 2025-03-31 |
| Per Robert Anderson | 2,36 | 2,36 | 2025-12-23 |
| John Moll | 1,88 | 1,88 | 2025-12-23 |
2026-02-11 Year End Report 2025
2026-05-07 Interim Report 2026-Q1
2026-06-18 Annual General Meeting 2025
2026-08-20 Interim Report 2026-Q2
2026-11-12 Interim Report 2026-Q3
2027-02-11 Year End Report 2026
